Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

[News]

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing.

More... (https://www.news-medical.net/news/20200723/Eikonoklastes-therapeutics-close-oversubscribed-seed-financing.aspx)